In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Valsartan improves ventriculo-vascular coupling index dose-dependently in heart failure with reduced left ventricular ejection fraction

Session Poster Session 3

Speaker Wook-Jin Chung

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : W-J Chung (Incheon,KR), H Choi (Incheon,KR), AY Chang (Incheon,KR), MS Shin (Incheon,KR), KY Park (Incheon,KR)

W-J Chung1 , H Choi1 , AY Chang1 , MS Shin1 , KY Park2 , 1Gachon University, Cardiology, Gachon Cardiovascular Research Institute - Incheon - Korea (Republic of) , 2Gachon University, CV Surgery, Gachon Cardiovascular Research Institute - Incheon - Korea (Republic of) ,


Objectives: We evaluated the effect of forced titration of valsartan in patients with HF.

Backgrounds: Heart failure is a clinical syndrome that causes significant morbidity and mortality. Recently, the ventriculo-vascular coupling index (VVI) was introduced as an independent prognostic factor that reflects the overall cardiovascular performance index in HF. However, it is not well elucidated whether forced titration of valsartan is effective or not on VVI in patients with HFrEF.

Methods: We evaluated the effect of valsartan stratified by dosage (non-ceiling dose vs ceiling dose). One-hundred-thirty-eight patients (59.3 ± 12.4 years old; 66% male) were force-titrated to the ceiling dose (n=81), but 57 patients did not reach the ceiling dose (non-ceiling dose; n=57). Biochemical studies including NT-proBNP, echocardiography including VVI, the treadmill test and the activity scale index (KASI) were assessed at baseline and after 24-weeks of therapy.

Results: The six month follow up showed significant improvement in NT-proBNP, LVEF, E/E’ ratio, and activity scale index in both groups. LVMI was significantly improved in the ceiling dose group but not in the non-ceiling dose group. Interestingly, a significant improvement in VVI was only observed in the ceiling dose group (from 2.4 ± 0.6 to 1.8±0.5, p<0.01).

Conclusions: The ceiling dose of valsartan for six months showed better improvement of VVI in patients with HFrEF compared with non-ceiling doses. We may need to consider escalating valsartan to the ceiling dose for the overall cardiovascular performance index in patients with HFrEF.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are